United States · Bill · HR
H.R. 2858 (116th)
FORWARD Act of 2019
Introduced
21 May 2019
Last action
22 May 2019 · Referred
Status
Referred to the Subcommittee on Health.
Sponsors
Kevin McCarthy, Rep. Schweikert, David [R-AZ-1], Karen Bass, Greg Stanton, Raúl Grijalva, Ann Kirkpatrick, Tom Cole, Duncan Hunter, Paul Cook, TJ Cox, Ken Calvert, Tom O'Halleran, Rep. Gottheimer, Josh [D-NJ-5]
Subjects
Healthcare, Education
Source updated
5 December 2025
Summary
Finding Orphan-disease Remedies With Antifungal Research and Development Act of 2019 or the FORWARD Act of 2019 This bill establishes programs to support the research of endemic fungal diseases and the development of antifungal drugs. (Endemic fungal diseases are fungal infections, e.g., Valley fever, that tend to to occur in specific geographic areas and affect particular at-risk populations, e.g., older adults.) Specifically, the bill establishes the Endemic Fungal Disease Working Group to review, coordinate, and make recommendations about the Department of Health and Human Services' (HHS) efforts to address endemic fungal diseases. The working group is comprised of experts from both relevant federal agencies and the private sector. The bill requires HHS to award grants for fungal disease research to local hospitals, higher education institutions, public health agencies, and nonprofit organizations. HHS also must establish an accelerated research program modeled after its research program to combat antibiotic resistant bacteria. The bill further requires the National Institutes of Health to develop a publicly-accessible server using blockchain technology to securely facilitate the sharing of fungal disease clinical research data. (Blockchain technology uses cryptography to create a digital ledger of transactions that can be simultaneously used and shared within a large, decentralized, and permanent network.) Additionally, the Food and Drug Administration (FDA) must prioritize the review of drugs to treat endemic fungal diseases and fast track the approval of such drugs at the request of applicants. The FDA must issue draft and final guidance related to the approval of antifungal products and therapies, including those that diagnose, treat, or prevent Valley fever.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
21 May 2019
Introduced
Referred to the House Committee on Energy and Commerce.
Source: IntroReferral
21 May 2019
Introduced
Introduced in House
Source: IntroReferral
21 May 2019
Introduced
Introduced in House
Source: IntroReferral
22 May 2019
Referred
Referred to the Subcommittee on Health.
Source: Committee
Votes
No vote records are attached yet.
Versions
- Introduced in House · 21 May 2019 · Official file
Documents
3 official files
Introduced in House (text)
Introduced in House (text)
Introduced in House · EN · 21 May 2019
Introduced in House (PDF)
Introduced in House · EN · 21 May 2019
Introduced in House
summary · EN · 21 May 2019
Sponsors
- Kevin McCarthy · R · Sponsor
- Rep. Schweikert, David [R-AZ-1] · R · Sponsor
- Karen Bass · D · Sponsor
- Greg Stanton · D · Sponsor
- Raúl Grijalva · D · Cosponsor
- Ann Kirkpatrick · D · Cosponsor
- Tom Cole · R · Cosponsor
- Duncan Hunter · R · Cosponsor
- Paul Cook · R · Cosponsor
- TJ Cox · D · Cosponsor
- Ken Calvert · R · Cosponsor
- Tom O'Halleran · D · Cosponsor
- Rep. Gottheimer, Josh [D-NJ-5] · D · Cosponsor
- · hsif00 · Standing
Related records
- related to → FORWARD Act of 2019
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/116th-congress/house-bill/2858
- Open data entity: https://api.congress.gov/v3/bill/116/hr/2858
- us · 116-hr-2858 · source updated 5 December 2025